This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
9 Mar 2011

RainDance Technologies and Ambry Genetics Ink ADME Deal

RainDance Technologies and Ambry Genetics announced a new collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion (ADME) genetic screening panel.

RainDance Technologies, Inc. and Ambry Genetics have established a collaboration for the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion (ADME) genetic screening panel for use on next-generation sequencing (NGS) systems.

The new ADME panel leverages RainDance's primer design methods and microdroplet-based RDT 1000 platform. It’s designed to provide scientists with the capacity to perform sequence analysis of entire coding regions associated with more than 220 key drug metabolism-linked genes including transporters, receptors, regulators and all pharmacodynamics and pharmacogenetic genes, as well as all FDA-identified pharmacogenomic biomarker genes.
<

Related News